GlassScriptPhysician profile
Jenny Chen
NPI 1861070328
$2,308.24
in general payments reported to CMS, 2019-2025
20 companies · $527 in 2025
The $527 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.14 · 2022: $362 · 2023: $434 · 2024: $929 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $279.94 | 2024 | |
| Emd Serono, INC. | $267.01 | 2022-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $207.38 | 2024 | |
| Biogen, INC. | $175.79 | 2025 | Skyclarys, Spinraza, Qalsody |
| Stryker Corporation | $159.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $146.96 | 2022-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $138.89 | 2025 | Nuplazid |
| Horizon Therapeutics Plc | $115.88 | 2022-2023 | Uplizna |
| Ucb, INC. | $115.10 | 2024 | Briviact |
| Jazz Pharmaceuticals INC. | $81.93 | 2024 | |
| Lilly USA, LLC | $76.18 | 2024-2025 | Amyvid, Kisunla |
| Pfizer INC. | $75.23 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.22 | 2023-2025 | Gammagard, Hyqvia |
| Genentech USA, INC. | $68.61 | 2022-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Averitas Pharma INC. | $65.69 | 2023-2024 | Qutenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.58 | 2024 | Wainua, Andexxa |
| Abbvie INC. | $29.78 | 2023 | Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $28.09 | 2022 | |
| Tg Therapeutics, INC. | $23.04 | 2025 | |
| Csl Behring | $16.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.